Anatomic Pathology Sample Clauses

Anatomic Pathology. Structured Report (APSR) provides templates for building surgical pathology reports (cancers, benign neoplasms as well as non-neoplastic conditions). The Anatomic Pathology group of HL7. The mission of the Anatomic Pathology working group is to develop and review implementation guides of HL7 standards and to enhance existing HL7 standards to support anatomic pathology use cases. It will work within HL7 as well as with external organizations to facilitate information interoperability in anatomic pathology, such as: a) Tracking of anatomic pathology specimens; b) Structuring and coding of anatomic 1 xxxx://xxx.xxx.xxx/Anatomic_Pathology/ reports; c) Integrating and consolidating anatomic pathology data and other data into the medical record (e.g. integrated composite reports); d) Ensuring consistency of anatomic pathology data and corresponding image association (includes both radiology and pathology imaging); e) Reviewing previously defined terms that differ between organizations (e.g. What is a “specimen”); f) Developing/reviewing value sets as needed (e.g. DICOM Specimen Embedding Media); e) Collecting and sharing data from biorepositories/tissue banks.
Sample 1
AutoNDA by SimpleDocs
Anatomic Pathology. Reference Lab and Office-Based Revenues. To align the incentives of all AmeriPath Pathologists operating within the SLA Territory, if AmeriPath closes on its acquisition of another pathology practice in the SLA Territory (the "Other Practice"), the Southwest Florida Division shall be credited with 45% (the "SFD Percentage") of the gross revenues derived by AmeriPath for all anatomic pathology reference lab and office-based services performed in, or originating out of, the SLA Territory (the "Reference-Office Revenues"), and the Other Practice shall be credited with 55% of the Reference-Office Revenues. After the closing, AmeriPath will provide Sellers with documentation substantiating the 45%/55% allocation described herein. If Sellers do not agree that such 45%/55% allocation is fair and accurate or, alternatively, agree upon another allocation of the Reference-Office Revenues, then this provision shall be void and each of the Southwest Florida Division and the Other
Sample 1
Anatomic Pathology. 2.2.2. Education (Medical / Dental Schools) 2.2.3. Veterinary labs
Sample 1
Anatomic Pathology. Clinical and research laboratories will be a primary focus for DakoCytomation. [***].
Sample 1

Related to Anatomic Pathology

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Animals The Hirer shall ensure that no animals (including birds) except guide dogs are brought into the premises, other than for a special event agreed to by the Village Hall. No animals whatsoever are to enter the kitchen at any time.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Prescription Claims against the Issuer or any Guarantor for the payment of principal or Additional Amounts, if any, on the Notes will be prescribed ten years after the applicable due date for payment thereof. Claims against the Issuer or any Guarantor for the payment of interest on the Notes will be prescribed five years after the applicable due date for payment of interest.

  • Virus Management Transfer Agent shall maintain a malware protection program designed to deter malware infections, detect the presence of malware within the Transfer Agent environment.

  • Medical Services We do not Cover medical services or dental services that are medical in nature, including any Hospital charges or prescription drug charges.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Information Technology The following applies to all contracts for information technology commodities and contractual services. “Information technology” is defined in section 287.012(15), F.S., to have the same meaning as provided in section 282.0041, F.S.

Time is Money Join Law Insider Premium to draft better contracts faster.